SEC filings
Bristol Myers Squibb (BMY)
Recent filings Bristol Myers Squibb made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000014272All filings on SEC.gov
10-QQuarterly report
Quarterly report
Bristol Myers Squibb (BMY) reported third-quarter 2026 total revenues of $13.1 billion, up 7% from a year earlier, with GAAP diluted EPS of $1.05 and non-GAAP diluted EPS of $1.35. …
8-KCurrent report
Results of Operations and Financial Condition; Regulation FD Disclosure
Bristol Myers Squibb reported third-quarter 2026 revenues of $13.1 billion, up 7%, and raised its full-year revenue guidance to $49.75–$50.25 billion, with GAAP EPS of $1.05 and non-GAAP EPS of $1.35. …
10-QQuarterly report
Quarterly report
Bristol Myers Squibb reported second-quarter 2026 total revenues of $12.973 billion, up 6%, and GAAP diluted EPS of $1.62, while advancing regulatory filings for iberdomide and mezigdomide in relapsed/refractory multiple myeloma and…
8-KCurrent report
Results of Operations and Financial Condition; Regulation FD Disclosure
Bristol Myers Squibb reported second-quarter 2026 revenues of $13.0 billion, up 6% year over year, with Growth Portfolio revenues up 15% to $7.6 billion, and raised its full-year 2026 revenue guidance to about $49.0–$50.0 billion and…
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Bristol Myers Squibb in Readster
Add Bristol Myers Squibb to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.